Scimitar Equity Blog

Cytori Therapeutics received U.S. Patent No. 7,651,684 (the ‘684 patent) which covers the CYTX’s methods for delivering adipose-derived stem and regenerative cell-enriched fat grafts into patients. The ‘684 patent specifically covers cell-enriched fat grafts to treat soft-tissue defects and urinary incontinence. In addition, the ‘684 patent covers methods for delivering cell-enriched fat grafts to a patient’s breast, wrinkles, lips, under the eyes, cheeks, chin, and other parts of the body and broadens current expansive patent portfolio covering adipose-derived cell therapies.

• The patent enhances their competive position while covering many significant enriched fat grafts,
• CYTX’s intellectual property portfolio currently includes 19 issued U.S. and international patents and 100 pending applications worldwide relating to the devices, methods and uses of adipose-derived stem and regenerative cells,
• The ‘684 patent is designed to protect the Celution® 800/CRS System, as well as future generations of the device, when approved for marketing and sale in the US,
• The ‘684 patent expands upon the  previously issued U.S. Patent No. 7,429,488 relating to automated methods of creating cell-applications for stem and regenerative cell-enriched fat grafting, allowing  development of  future generation therapeutics and pursue solutions for patients with unmet medical needs in tissue damage indications, including breast reconstruction.